EUVIMEDEUVIMED entdecken
Open Access

Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals

Tao Tian, Yang Wang, Wei Guo

American Journal of Translational Research · 2026 · 18 (7) · 5974-5987

DOI: 10.62347/cfkg8762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Tao Tian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Beijing Friendship Hospital, Capital Medical University Beijing 100050, China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomaPD-1 inhibitorliver functiontransarterial chemoembolizationtreatment intervaltumor response

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Beijing Friendship Hospital, Capital Medical University Beijing 100050, China.
  • Department of Interventional and Vascular Surgery, Jincheng People's Hospital Jincheng 048026, Shanxi, China.

Zitieren

APA

Tian, T., Wang, Y., & Guo, W. (2026). Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals. American Journal of Translational Research, 18(7), 5974-5987. https://doi.org/10.62347/cfkg8762

Vancouver

Tian T, Wang Y, Guo W. Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals. American Journal of Translational Research. 2026;18(7):5974-5987. doi:10.62347/cfkg8762

BibTeX
@article{Tian2026,
  author = {Tian, Tao and Wang, Yang and Guo, Wei},
  title = {Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals},
  journal = {American Journal of Translational Research},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {5974--5987},
  doi = {10.62347/cfkg8762}
}
Kostenlos starten →